source
- Beam Therapeutics reports year-long reduction in sickle cell crises in phase 1/2 risto-cel studyBeam Therapeutics disclosed data from its phase 1/2 trial of risto-cel, a base-edited autologous cell therapy targeting the BCL11A gene in sickle cell disease. The trial enrolled 31 adults and ado…
- Oura to buy AI virtual care firm Counsel Health for $625 million, expanding in-app health servicesOura, known for its smart ring and health tracking, announced it will acquire Counsel Health, an AI-driven virtual primary-care provider, for $625 million in cash. The acquisition is slated to clo…Fierce Biotech · 11h agoDealPositive